See more : First IC Corporation (FIEB) Income Statement Analysis – Financial Results
Complete financial analysis of Doseology Sciences Inc. (MOOD.CN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Doseology Sciences Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- NEXION Group Ltd (NNG.AX) Income Statement Analysis – Financial Results
- Premier Explosives Limited (PREMEXPLQ.BO) Income Statement Analysis – Financial Results
- Chori Co., Ltd. (8014.T) Income Statement Analysis – Financial Results
- Prenetics Global Limited (PRENW) Income Statement Analysis – Financial Results
- Arch Resources, Inc. (ARCH) Income Statement Analysis – Financial Results
Doseology Sciences Inc. (MOOD.CN)
About Doseology Sciences Inc.
Doseology Sciences Inc. engages in the cultivation and extraction of nutraceutical and pharmaceutical products in Canada. It focuses on research, development, and sale of medicinal mushroom products, including tinctures and powders. The company sells its products online through doseology.com. Doseology Sciences Inc. was incorporated in 2019 and is based in Kelowna, Canada.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
---|---|---|---|---|---|
Revenue | 98.52K | 43.09K | 16.05K | 0.00 | 0.00 |
Cost of Revenue | 134.61K | 1.80K | 164.43K | 0.00 | 0.00 |
Gross Profit | -36.08K | 41.29K | -148.38K | 0.00 | 0.00 |
Gross Profit Ratio | -36.63% | 95.82% | -924.59% | 0.00% | 0.00% |
Research & Development | 0.00 | 500.00 | 61.72K | 112.41K | 0.00 |
General & Administrative | 234.33K | 586.87K | 1.28M | 1.19M | 0.00 |
Selling & Marketing | 115.60K | 172.91K | 191.38K | 170.25K | 0.00 |
SG&A | 349.93K | 759.78K | 1.47M | 1.36M | 431.63K |
Other Expenses | 0.00 | 190.90K | 139.53K | 0.00 | 0.00 |
Operating Expenses | 72.09K | 873.46K | 1.67M | 1.57M | 431.63K |
Cost & Expenses | 476.16K | 875.26K | 1.83M | 1.57M | 431.63K |
Interest Income | 29.29K | 65.04K | 6.84K | 3.02K | 0.00 |
Interest Expense | 0.00 | 36.14K | 75.77K | 68.30K | 0.00 |
Depreciation & Amortization | 20.37K | 66.09K | 139.53K | 92.83K | 0.00 |
EBITDA | -319.48K | -1.78M | -1.72M | -1.47M | -431.63K |
EBITDA Ratio | -324.27% | -1,627.00% | -10,407.98% | 0.00% | 0.00% |
Operating Income | -377.63K | -767.13K | -1.82M | -1.56M | -431.63K |
Operating Income Ratio | -383.30% | -1,780.39% | -11,320.05% | 0.00% | 0.00% |
Total Other Income/Expenses | 37.79K | -949.37K | -122.68K | -62.30K | 0.00 |
Income Before Tax | -339.85K | -1.78M | -1.94M | -1.63M | -431.63K |
Income Before Tax Ratio | -344.95% | -4,134.66% | -12,084.50% | 0.00% | 0.00% |
Income Tax Expense | 0.00 | 36.14K | 75.77K | 68.30K | 0.00 |
Net Income | -339.85K | -1.78M | -1.94M | -1.63M | -431.63K |
Net Income Ratio | -344.95% | -4,134.66% | -12,084.50% | 0.00% | 0.00% |
EPS | -0.08 | -0.43 | -0.50 | 0.00 | -0.12 |
EPS Diluted | -0.08 | -0.43 | -0.50 | 0.00 | -0.12 |
Weighted Avg Shares Out | 4.26M | 4.11M | 3.91M | 0.00 | 3.70M |
Weighted Avg Shares Out (Dil) | 4.26M | 4.11M | 3.91M | 0.00 | 3.70M |
Source: https://incomestatements.info
Category: Stock Reports